The significance of 'no significant difference'.

Area of Science:

• Radiology
• Pharmacology
• Clinical Trials

Background:

• Patients generally report less discomfort with low osmolality contrast media (LOM) compared to high osmolar media (HOM).
• Statistical evidence from high-quality controlled trials demonstrating a lower incidence of significant adverse reactions (e.g., anaphylaxis) with LOM is limited.
• Existing studies may be underpowered due to small sample sizes, often dictated by regulatory requirements for drug registration.

Purpose of the Study:

• To address the statistical challenges in evaluating rare adverse events associated with contrast media.
• To determine the required sample size for clinical trials to reliably detect clinically significant differences in complication rates between LOM and HOM.

Main Methods:

• The study discusses the statistical principles for sample size calculation in clinical trials.
• It analyzes the power needed to detect differences in low-incidence events (e.g., reducing complication rates from 10% to 5%).

Main Results:

• The paper highlights that small study sizes (15-60 cases per center) are insufficient to demonstrate statistically significant differences for rare complications.
• Absence of statistical significance in small trials does not equate to absence of a real difference in complication frequency.

Conclusions:

• Larger sample sizes are crucial for statistically verifying clinically meaningful reductions in adverse event rates with low osmolality contrast media.
• Methodological considerations for trial design are essential to accurately assess the safety profile of contrast media.